Immuron (ASX:IMC) reported sales of AU$1.6 million for its over-the-counter immune supplement Travelan in Australia for the fiscal first quarter was up 52% year-over-year, and sales of AU$2 million globally, increasing 34% from the prior corresponding period, according to a Monday Australian bourse filing.

The continued growth in Australia can be attributed to "increased awareness and consideration" driven by marketing, as well as same-store growth as a result of market promotions.

Its shares fell 6% in recent trading on Monday.